Condition: AML - Acute Myeloid Leukemia · Sponsor: Technische Universität Dresden
Explore the best tolerable and efficacious dose of Gilteritinib when combined with standard treatment with Venetoclax and Azacitidine in AML patients with FLT3 mutations which are ineligible for intensive chemotherapy
This description comes directly from the study's public registry record.
Prof. Dr. Christoph Röllig, MD, MSc · +49 351 458 4190 · sequence@ukdd.de
Always discuss trial participation with your own doctor first.
| Technische Universität Dresden | Dresden, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06696183